Translational Development Acquisition Corp. Files S-1/A Amendment

TL;DR

SPAC filing update from Translational Development Acquisition Corp. - looks like they're still working on their deal.

AI Summary

Translational Development Acquisition Corp. filed an S-1/A amendment on December 19, 2024, for its registration statement. The company, incorporated in the Cayman Islands, is a blank check company with its principal executive offices located at 52 E 83rd St., New York, NY 10028. Michael B. Hoffman is listed as the Chief Executive Officer.

Why It Matters

This filing indicates an update to the company's registration, which is a step in its process to potentially acquire or merge with another business.

Risk Assessment

Risk Level: medium — As a blank check company (SPAC), its success is highly dependent on finding and completing a suitable merger, which carries inherent risks.

Key Numbers

• 333-282763 — SEC File Number (Identifies this specific registration filing with the SEC.)

Key Players & Entities

• Translational Development Acquisition Corp. (company) — Registrant
• December 19, 2024 (date) — Filing Date
• Cayman Islands (jurisdiction) — Place of Incorporation
• Michael B. Hoffman (person) — Chief Executive Officer
• 52 E 83rd St., New York, NY 10028 (address) — Principal Executive Offices
• 333-282763 (registration_number) — SEC File Number

FAQ

Key Financial Figures

• $150,000,000 — ational Development Acquisition Corp. $150,000,000 15,000,000 Units Translational Deve
• $10.00 — ies. Each unit has an offering price of $10.00 and consists of one Class A ordinary sh
• $11.50 — ne Class A ordinary share at a price of $11.50 per share, subject to adjustment as des
• $1.00 — e, subject to adjustment, at a price of $1.00 per warrant, or $6,400,000 (or $7,075,0
• $6,400,000 — nt, at a price of $1.00 per warrant, or $6,400,000 (or $7,075,000 if the underwriters' ove
• $7,075,000 — of $1.00 per warrant, or $6,400,000 (or $7,075,000 if the underwriters' over-allotment opt
• $3,250,000 — rrants at a price of $1.00 per warrant ($3,250,000 in the aggregate) in a private placemen
• $25,000 — Our former sponsor paid an aggregate of $25,000, or approximately $0.006 per founder sh
• $0.006 — aggregate of $25,000, or approximately $0.006 per founder share, and, accordingly, yo
• $100,000 — interest (less taxes payable and up to $100,000 of interest to pay dissolution expenses
• $0.20 — 9.45 $ 141,750,000 1) Includes $0.20 per unit (including any units sold purs
• $3,000,000 — ption to purchase additional units), or $3,000,000 in the aggregate (or up to $3,450,000 i
• $3,450,000 — r $3,000,000 in the aggregate (or up to $3,450,000 if the underwriters' over-allotment opt
• $0.35 — closing of this offering. Also includes $0.35 per unit on all units sold including th
• $5,250,000 — option to purchase additional units, or $5,250,000 in the aggregate (or up to $6,037,500 i

Filing Documents

• tm2422367-9_s1a.htm (S-1/A) — 2574KB
• tm2422367d10_ex1-1.htm (EX-1.1) — 257KB
• tm2422367d10_ex3-2.htm (EX-3.2) — 260KB
• tm2422367d10_ex4-4.htm (EX-4.4) — 98KB
• tm2422367d10_ex5-1.htm (EX-5.1) — 49KB
• tm2422367d10_ex10-4.htm (EX-10.4) — 47KB
• tm2422367d10_ex10-5.htm (EX-10.5) — 85KB
• tm2422367d10_ex10-8.htm (EX-10.8) — 43KB
• tm2422367d10_ex10-9.htm (EX-10.9) — 46KB
• tm2422367d10_ex23-1.htm (EX-23.1) — 2KB
• tm2422367d10_ex5-1img001.jpg (GRAPHIC) — 4KB
• tm2422367d10_ex5-1img002.jpg (GRAPHIC) — 6KB
• 0001104659-24-129831.txt ( ) — 3476KB

Use of Proceeds

Use of Proceeds 100 Dividend Policy 104

Dilution

Dilution 105 Capitalization 109

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 111 Proposed Business 118 Effecting our Initial Business Combination 129 Management 152 Principal Shareholders 162 Certain Relationships and Related Party Transactions 167

Description of Securities

Description of Securities 170 Taxation 192

Underwriting

Underwriting 204 Legal Matters 215 Experts 215 Where You Can Find Additional Information 215 Index to Financial Statements F-1 We are responsible for the information contained in this prospectus. We have not, and the underwriters have not, authorized anyone to provide you with information that is different from or inconsistent with that contained in this prospectus. We are not, and the underwriters are not, making an offer to sell securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than the date on the front of this prospectus. i TABLE OF CONTENTS Trademarks This prospectus contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the or symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. TABLE OF CONTENTS SUMMARY This summary only highlights the more detailed information appearing elsewhere in this prospectus. As this is a summary, it does not contain all of the information that you should consider in making an investment decision. You should read this entire prospectus carefully, including the information under "Risk Factors" and our financial statements and the related notes included elsewhere in this prospectus, before investing. Unless otherwise stated in this prospectus or the context otherwise requires, references to: "Companies Act" are to the Companies Act (Revised) of the Cayman Islands as the same may be amended from time to time; "

View Full Filing

View this S-1/A filing on SEC EDGAR